RETHINK
THE TREATMENT OF
REFLUX The LINX® Reflux
Management System, a minimally invasive, long-term, surgical treatment option.
Most patients no longer required medication1
• After 5 years, 85% of patients were able to stop daily PPI medication.
Regurgitation score was reduced1
• The proportion of patients reporting moderate-to-severe regurgitation decreased, from 57% before implantation to 1.2% at 5 years.
The LINX device is restricted to sale and use by a licensed practitioner. Please contact an implanting physician to discuss suitability, risks, and side effects with LINX. For more information please visit
www.toraxmedical.co.uk/linx
REFERENCE 1. Ganz et al: Long-Term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clinical Gastroenterology and Hepatology 2015.
Torax® Medical, Inc. and the LINX® Reflux Management System are trademarks of Torax Medical, Incorporated. Doc no: 4841-1 Rev 1. Date of preparation: Oct 2017.
www.toraxmedical.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48